These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 32471447)
21. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU; Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930 [TBL] [Abstract][Full Text] [Related]
22. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Pinato DJ; Karamanakos G; Arizumi T; Adjogatse D; Kim YW; Stebbing J; Kudo M; Jang JW; Sharma R Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1270-81. PubMed ID: 25327965 [TBL] [Abstract][Full Text] [Related]
23. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study. Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874 [TBL] [Abstract][Full Text] [Related]
24. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization. Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926 [TBL] [Abstract][Full Text] [Related]
25. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis. Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326 [TBL] [Abstract][Full Text] [Related]
26. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Molinari M; Kachura JR; Dixon E; Rajan DK; Hayeems EB; Asch MR; Benjamin MS; Sherman M; Gallinger S; Burnett B; Feld R; Chen E; Greig PD; Grant DR; Knox JJ Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):684-92. PubMed ID: 17100154 [TBL] [Abstract][Full Text] [Related]
27. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. Liu G; Ouyang Q; Xia F; Fan G; Yu J; Zhang C; Wang D HPB (Oxford); 2019 Jan; 21(1):107-113. PubMed ID: 30017783 [TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939 [TBL] [Abstract][Full Text] [Related]
29. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199 [TBL] [Abstract][Full Text] [Related]
31. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors. Sohn W; Choi MS; Cho JY; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Yoo BC Gut Liver; 2014 Sep; 8(5):543-51. PubMed ID: 25071073 [TBL] [Abstract][Full Text] [Related]
32. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C. Li L; Gou CY; Li JY; Achakzai R; Li XH Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma. Zhu SL; Zhong JH; Ke Y; Ma L; You XM; Li LQ World J Gastroenterol; 2015 Aug; 21(32):9630-7. PubMed ID: 26327771 [TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884 [TBL] [Abstract][Full Text] [Related]
35. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Shim JH; Kim KM; Lee YJ; Ko GY; Yoon HK; Sung KB; Park KM; Lee SG; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ Ann Surg Oncol; 2010 Mar; 17(3):869-77. PubMed ID: 20033326 [TBL] [Abstract][Full Text] [Related]
36. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621 [TBL] [Abstract][Full Text] [Related]
37. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma. Jeong SO; Kim EB; Jeong SW; Jang JY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ; Goo DE; Park SY Gut Liver; 2017 May; 11(3):409-416. PubMed ID: 28208001 [TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Müller L; Hahn F; Mähringer-Kunz A; Stoehr F; Gairing SJ; Foerster F; Weinmann A; Galle PR; Mittler J; Pinto Dos Santos D; Pitton MB; Düber C; Fehrenbach U; Auer TA; Gebauer B; Kloeckner R United European Gastroenterol J; 2022 Feb; 10(1):41-53. PubMed ID: 34918471 [TBL] [Abstract][Full Text] [Related]
39. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302 [TBL] [Abstract][Full Text] [Related]
40. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study. Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]